- Home
- NBH vs BDTX Comparison
NBH vs BDTX Comparison
Compare NBH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBH | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 116.8M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBH | BDTX |
|---|---|---|
| Price | $10.26 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 80.3K | ★ 564.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.47 | $1.20 |
| 52 Week High | $10.64 | $4.94 |
Technical Indicators
Market Signals| Indicator | NBH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 40.78 |
| Support Level | $10.21 | $1.93 |
| Resistance Level | $10.37 | $2.67 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.13 | 26.76 |
Price Performance
Historical ComparisonAbout NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.